01
AECQS methodology memorandum
Research objectives, eligible markets, data requirements, signal construction, portfolio integration, modeled execution, validation stages and evidence-classification rules.
Public summary
02
Data-lineage summary
Source families, contract and symbol handling, normalization, corporate-action treatment, timestamp conventions, transformations, quality controls and known gaps.
Controlled review
03
Backtest verification report
Reproduction procedures, accounting reconciliation, run identifiers, result checks and exceptions. Current verification is internal; no independent audit is represented.
Internal status
04
Cost and slippage methodology
Commission, fee, spread, slippage, financing and sensitivity conventions, including base, adverse and severe implementation paths.
Controlled review
05
Model-risk statement
Overfitting, selection bias, survivorship bias, non-stationarity, execution shortfall, parameter instability, leverage and model-governance risks.
Public summary
06
Version and change-control policy
Named releases, immutable checkpoints, approval records, change rationale, regression testing, deprecation and research-to-production boundaries.
Policy in development
07
Capacity and liquidity study
Participation limits, volume and open-interest constraints, market impact, liquidation horizons, margin stress and instrument-level concentration.
Not yet verified
08
Ownership and IP statement
Company reservation of AECQS Growth, AECQS Controlled transaction boundaries, code and research ownership, confidentiality and permitted-use restrictions.
Counsel review advised
09
Cybersecurity and continuity summary
Access control, credential handling, backups, recovery objectives, dependency management, incident escalation and continuity responsibilities.
Framework in development
10
Legal-entity information
Entity name, formation jurisdiction, leadership, registered status and the boundary between company information and regulated activity.
Public summary
11
Legal and technical contact
A single confidential intake path for counsel, technical reviewers, institutions, family offices, strategic acquirers and qualified counterparties.
Available